The report covers forecast and analysis for the leukemia therapeutics market on a global and regional level. The study provides historic data from 2014 along with a forecast for 2017 to 2022 based revenue (USD Billion). The study includes drivers and restraints for the leukemia therapeutics market along with the impact they have on the demand over the forecast period. Additionally, the report includes the study of opportunities available in the leukemia therapeutics market on a global level.
In order to give the users of this report a comprehensive view on the leukemia therapeutics market, we have included competitive landscape and analysis of Porter’s Five Forces model for the market. The study encompasses a market attractiveness analysis, wherein type and therapy segments are benchmarked based on their market size, growth rate, and general attractiveness.
The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments of the market including acquisitions & mergers, new therapy launch, agreements, partnerships, collaborations & joint ventures, research& development, therapy and regional expansion of major participants involved in the market on a global and regional basis.
The study provides a decisive view on the leukemia therapeutics market by segmenting the market based on type, therapy, and regions. All the segments have been analyzed based on present and future trends and the market is estimated from 2016 to 2022. Based on the type the market is segmented into chronic leukemia, acute leukemia and other. Chronic leukemia is further classified into chronic lymphatic leukemia and chronic myeloid leukemia. Also, acute leukemia is further sub-segmented into acute lymphatic leukemia and acute myeloid leukemia. Based on therapy the market is segmented into chemotherapy, biological therapy, radiation therapy, targeted therapy and others. The regional segmentation includes the current and forecast demand for North America, Europe, Asia-Pacific, Latin America and the Middle East & Africa with its further bifurcation into major countries including the U.S. Germany, France, UK, China, Japan, India, and Brazil. This segmentation includes demand for leukemia therapeutics based on individual therapy in all the regions and countries.
The report also includes detailed profiles of end players such as F. Hoffmann-La Roche Ltd., Amgen, Bristol-Myers Squibb, Novartis International AG., Pfizer, Teva Pharmaceuticals, GlaxoSmithKline plc., Genzyme Corporation, AbbVie Inc. and ARIAD Pharmaceuticals, Inc. among others.
This report segments the global leukemia therapeutics market as follows:
Global Leukemia Therapeutics Market: Type Segment Analysis
- Chronic leukemia
- Chronic lymphatic leukemia
- Chronic myeloid leukemia
- Acute leukemia
- Acute lymphatic leukemia
- Acute myeloid leukemia
- Others
Global Leukemia Therapeutics Market: Therapy Segment Analysis
- Chemotherapy
- Biological Therapy
- Radiation therapy
- Targeted therapy
- Other
Global Leukemia Therapeutics Market: Regional Segment Analysis
- North America
- U.S.
- Europe
- UK
- France
- Germany
- Asia Pacific
- China
- Japan
- India
- Latin America
- Brazil
- Middle East and Africa
